Table 3.
Summary of main results of diagnostic value of concentration of cfDNA for breast cancer.
| Study group | N | Sensitivity (95% CI) | I2 (%) | Specificity (95% CI) | I2 (%) | DOR (95% CI) | I2 (%) | AUC (95% CI) | |
|---|---|---|---|---|---|---|---|---|---|
| All | 13 | 87% (73%−94%) | 96.49 | 87% (79%−93%) | 89.91 | 32.93(13.52–80.19) | 85.8 | 0.93(0.91–0.95) | |
| Sample of cfDNA | plasma | 7 | 94% (80%−98%) | 98.52 | 89% (75%−96%) | 94.26 | 79.11(19.13–327.12) | 85.0 | 0.97(0.95–0.98) |
| serum | 6 | 74% (56%−86%) | 92.54 | 85% (73%−92%) | 85.77 | 15.80 (4.51–55.34) | 88.3 | 0.87(0.84–0.90) | |
| Time of sample collection | before surgery | 11 | 90% (78%−96%) | 94.1 | 88% (78%−94%) | 89.17 | 50.15(17.49–143.79) | 86.1 | 0.95(0.93–0.96) |
| Test method | RT–qPCR | 9 | 88% (77%−95%) | 97.52 | 89% (77%−95%) | 93.66 | 46.29(15.82–135.45) | 86.8 | 0.95(0.93–0.96) |
| Not RT–qPCR | 4 | 85% (29%−99%) | 95.04 | 84% (73%−91%) | 74.64 | 16.60 (2.62–105.31) | 85.0 | 0.88(0.85–0.91) |
N, number of studies.